<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041768</url>
  </required_header>
  <id_info>
    <org_study_id>DIA-CHIR-MULT-BMI 30-35</org_study_id>
    <nct_id>NCT01041768</nct_id>
  </id_info>
  <brief_title>Multicentric Prospective Randomized Trial on Surgery Versus Standard Medical Care in Type 2 Diabetic Patients BMI 30-35</brief_title>
  <acronym>DIA-CHIR-MULT</acronym>
  <official_title>Multicentric Prospective Randomized Controlled Trial on the Effect of Gastric Bypass and Bilopancreatic Diversion on Type 2 Diabetes Mellitus in Patients With BMI Between 30 and 35</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale di Desenzano del Garda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Santa Maria Degli Angeli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Multimedica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Humanitas Gavazzeni di Bergamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ente Ospedaliero Ospedali Galliera</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale S. Giovanni Bosco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Policlinico Universitario Agostino Gemelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale S. Timoteo, Termoli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Marino, Cagliari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Pietro Fatebenefratelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda ospedaliera Garibaldi Catania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      200 type 2 diabetic patients -BMI between 30-35- will be submitted to bariatric surgery
      (biliopancreatic diversion BPD or gastric bypass GBP ) and 100 will receive standard medical
      treatment.

      Subjects will be monitored during a 5 year period to assess the effects of the surgical
      procedures on diabetes resolution and control at 1, 3 and 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicentric prospective 2-arm randomized controlled trial. Only Centers with
      at least 50 bariatric surgeries performed during the time window January 2007 and September
      2008 will be allowed to participate in the study.

      Each Collaborating Center participating in the study will perform only one type of surgical
      procedure (GBP or BPD), depending on which one it is more familiar with.

      Patients will be randomly assigned with a 2 to 1 ratio to receive either bariatric surgery
      (BS) (either GBP or BPD) or standard antidiabetic care (AC). The randomization will be
      centralized in the Coordinating Center. Patients assigned to BS will undergo GBP or BPD,
      depending on each Collaborating Center. Recruitment will continue, independently of the
      number of recruited patients per center, until the target of 200 GBP+BPD patients, and 100 AC
      patients will be attained.

      After one year since enrollment, patients in AC group will be offered the choice to undergo
      one of the two surgical procedures, and then will follow the same protocol study as the other
      surgical patients. In addition, each Collaborating Center will be responsible for selecting
      one diabetic subject for each operated patient, matched as closely as possible with the
      patients assigned to surgical therapy, from the local population in medical treatment. These
      patients will serve as controls for long term mortality and morbidity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving diabetes complete remission (HbA1c 6% or below) or diabetes control (HbA1c between 7% and 6.1%) on free diet and with no antidiabetic medical therapy.</measure>
    <time_frame>year 1, 3, 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stable reduction of preoperative HbA1c; BMI; mortality/morbidity; Major components of the metabolic syndrome; Diabetes complications; Improvement of beta-cell function; insulin resistance reduction ; Overall and CV disease mortality.</measure>
    <time_frame>at and post surgery, 1,3, 5 years since randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>antidiabetic medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bariatric Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop</description>
    <arm_group_label>antidiabetic medical therapy</arm_group_label>
    <arm_group_label>Bariatric Surgery</arm_group_label>
    <other_name>biliopancreatic diversion</other_name>
    <other_name>gastric bypass</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥30 and ≤34.9 kg/m2

          -  age between 35 and 70 years

          -  duration of diabetes ≥ 5 years

          -  poor glycemic control (i.e., HbA1c ≥ 8%) in spite a medical antidiabetic therapy in
             accordance with good clinical practice (GCP)

          -  presence of significant co-morbidities or complications (such as dyslipidemia,
             arterial hypertension, impaired renal function, neuropathy, retinopathy, CVD)

        Exclusion Criteria:

          -  specific contraindication to obesity surgery or GBP or BPD, including any gastric
             alteration specifically contraindicating GBP

          -  HbA1c &lt; 8%

          -  positive autoantibodies anti-pancreas islet

          -  serum C-peptide &lt; 0.5 ng/ml

          -  pregnancy

          -  medical conditions requiring acute hospitalisation

          -  severe diabetes complications or associated medical conditions (such as blindness,
             end-stage renal failure, liver cirrhosis, malignancy, chronic congestive heart failure

          -  recent (within preceding 12 months) myocardial infarction, stroke or TIA

          -  unstable angina pectoris

          -  psychological conditions which may hamper patient's cooperation

          -  geographic inaccessibility

          -  any condition which, in the judgement of the Investigator, may make risky the
             participation in the study or bias the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Scopinaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria &quot;San Martino&quot;, Genova, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Scopinaro, MD</last_name>
    <phone>+39 010 3537301</phone>
    <email>nicola.scopinaro@unige.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;San Martino&quot;</name>
      <address>
        <city>Genova</city>
        <zip>15067</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Scopinaro, MD</last_name>
      <phone>+39 010 3537301</phone>
      <email>nicola.scopinaro@unige.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Scopinaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2009</study_first_submitted>
  <study_first_submitted_qc>December 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2010</study_first_posted>
  <last_update_submitted>March 29, 2010</last_update_submitted>
  <last_update_submitted_qc>March 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nicola Scopinaro, Prof.</name_title>
    <organization>Azienda Ospedaliera Universitaria &quot;San Martino&quot;</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

